First-in-class drug discovery
First written in FY2017. 14 of 15 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「Based on the results of basic research, our group conducts drug discovery research into small-molecule drugs, cancer peptide vaccines and antibody drugs, among others, with the aim of clinical application and first-in-class drug discovery.」
The company continues to pursue the goal of translating basic research findings into clinical applications and achieving first-in-class drug discovery. - FY2023-Q3RestatedAnnual report
「Based on the results of basic research, our group conducts drug discovery research into small-molecule drugs, cancer peptide vaccines and antibody drugs, among others, with the aim of clinical application and first-in-class drug discovery.」
The company continues to pursue the goal of translating basic research findings into clinical applications and achieving first-in-class drug discovery. - FY2023-Q1RestatedAnnual report
「Based on the results of basic research, our group conducts drug discovery research into small-molecule drugs, cancer peptide vaccines and antibody drugs, among others, with the aim of clinical application and first-in-class drug discovery.」
The company continues to pursue the goal of translating basic research findings into clinical applications and achieving first-in-class drug discovery. - FY2022-Q3RestatedAnnual report
「Based on the results of basic research, our group conducts drug discovery research into small-molecule drugs, cancer peptide vaccines and antibody drugs, among others, with the aim of clinical application and first-in-class drug discovery.」
The company continues to pursue the goal of translating basic research findings into clinical applications and achieving first-in-class drug discovery. - FY2022-Q1RestatedAnnual report
「Based on the results of basic research, our group conducts drug discovery research into small-molecule drugs, cancer peptide vaccines and antibody drugs, among others, with the aim of clinical application and first-in-class drug discovery.」
The company continues to pursue the goal of translating basic research findings into clinical applications and achieving first-in-class drug discovery. - FY2021-Q3RestatedAnnual report
「Based on the results of basic research, our group conducts drug discovery research into small-molecule drugs, cancer peptide vaccines and antibody drugs, among others, with the aim of clinical application and first-in-class drug discovery.」
The company continues to pursue the goal of translating basic research findings into clinical applications and achieving first-in-class drug discovery. - FY2021-Q2RestatedAnnual report
「Based on the results of basic research, our group conducts drug discovery research into small-molecule drugs, cancer peptide vaccines and antibody drugs, among others, with the aim of clinical application and first-in-class drug discovery.」
The company continues to pursue the goal of translating basic research findings into clinical applications and achieving first-in-class drug discovery. - FY2021-Q1RestatedAnnual report
「Based on the results of basic research, our group conducts drug discovery research into small-molecule drugs, cancer peptide vaccines and antibody drugs, among others, with the aim of clinical application and first-in-class drug discovery.」
The company continues to pursue the goal of translating basic research findings into clinical applications and achieving first-in-class drug discovery. - FY2020-Q3RestatedAnnual report
「Based on the results of basic research, our group conducts drug discovery research into small-molecule drugs, cancer peptide vaccines and antibody drugs, among others, with the aim of clinical application and first-in-class drug discovery.」
The company continues to pursue the goal of translating basic research findings into clinical applications and achieving first-in-class drug discovery. - FY2020-Q2RestatedAnnual report
「Based on the results of basic research, our group conducts drug discovery research into small-molecule drugs, cancer peptide vaccines and antibody drugs, among others, with the aim of clinical application and first-in-class drug discovery.」
The company continues to pursue the goal of translating basic research findings into clinical applications and achieving first-in-class drug discovery. - FY2020-Q1RestatedAnnual report
「Based on the results of basic research, our group conducts drug discovery research into small-molecule drugs, cancer peptide vaccines and antibody drugs, among others, with the aim of clinical application and first-in-class drug discovery.」
The company continues to pursue the goal of translating basic research findings into clinical applications and achieving first-in-class drug discovery. - FY2018RestatedAnnual report
「Animal studies have already confirmed potent antitumor effects of OTS167 against lung, prostate, breast and pancreatic cancers, among others. OTS167 is also a molecularly targeted therapeutic with a novel mechanism of action and is first-in-class.」
The disclosure continues to position OTS167 as a first-in-class molecularly targeted therapeutic with a novel mechanism of action. - FY2018-Q3RestatedAnnual report
「Animal studies have already confirmed potent antitumor effects of OTS167 against lung, prostate, breast and pancreatic cancers, among others. OTS167 is also a molecularly targeted therapeutic with a novel mechanism of action and is first-in-class.」
OTS167 continues to be positioned as a first-in-class molecularly targeted therapeutic. - FY2018-Q2RestatedAnnual report
「Animal studies have already confirmed potent antitumor effects of OTS167 against lung, prostate, breast and pancreatic cancers, among others. OTS167 is also a molecularly targeted therapeutic with a novel mechanism of action and is first-in-class.」
OTS167 continues to be positioned as a first-in-class molecularly targeted therapeutic. - FY2017First statedAnnual report
「Based on the results of basic research, our group conducts drug discovery research into small-molecule drugs, cancer-specific peptide vaccines and antibody drugs, among others, with the aim of clinical application and first-in-class drug discovery.」
The company has stated its goal of translating basic research findings into clinical applications and pursuing drug discovery with novel mechanisms of action distinct from existing drugs.